ORL-1 Receptor Modulators for Low-Dependency Sleep Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sleep disorder treatments, such as benzodiazepines and z-drugs, carry a high risk of abuse and addiction, and other drugs may have adverse side effects, while current ORL-1 receptor modulators have not effectively addressed various sleep disorders, particularly those related to alcohol use.
Innovation Solution
Development of ORL-1 receptor modulating compounds, including formulas (1), (1A), (1B), (1C), (1D), and (1E), which are administered to treat or prevent sleep disorders like insomnia, hypersomnia, and alcohol-induced sleep disorders with reduced side effects and lower addiction potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepines or z-drugs are used to treat sleep disorders, then sleep induction efficacy is improved, but risk of abuse and addiction increases
Solution Approach 1:
The patent changes the pharmacological parameter by selecting compounds with specific ORL-1 receptor binding affinity (Ki values in nanomolar range) while deliberately avoiding GABAergic mechanisms. This parameter change in receptor target selection achieves sleep induction without the addictive properties of benzodiazepines and z-drugs
Solution Approach 2:
The patent introduces ORL-1 receptor modulators as an intermediary mechanism between traditional GABAergic drugs and the desired sleep effect. These compounds act through a different neural pathway (ORL-1 receptors rather than GABA receptors), providing sleep induction through an alternative mediator that does not carry the same abuse potential
2Reliability
If existing sleep disorder drugs are administered, then sleep quality is improved, but adverse side effects increase
Solution Approach 1:
The patent changes the chemical and pharmacological parameters by developing compounds with specific molecular structures (formulas I, II, III with defined substituents) and specific ORL-1 receptor affinity profiles. This parameter optimization achieves effective sleep treatment while minimizing side effects through selective receptor interaction
Solution Approach 2:
The patent segments the sleep regulation mechanism by targeting ORL-1 receptors specifically, separating this function from the broader GABAergic system. This segmentation allows for selective modulation of sleep-wake cycles without affecting other GABA-mediated functions, thereby reducing adverse side effects
3Reliability
If current ORL-1 receptor modulators are used, then some sleep symptoms are addressed, but efficacy in alcohol-induced sleep disorders is insufficient
Solution Approach 1:
The patent enhances universality by developing ORL-1 receptor modulators that effectively treat multiple types of sleep disorders including primary insomnia, circadian rhythm disorders, and alcohol-induced sleep disorders. The compounds demonstrate broad applicability across different etiology categories, making them versatile for various clinical presentations
Data Source
AI summary
The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1) (1), or a compound of formula (1A), (1B), (1C), (1D)), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.